We have performed a genome-wide analysis of copy number changes in breast and colorectal tumors using approaches that can reliably detect homozygous deletions and amplifications. We found that the number of genes altered by major copy number changes, deletion of all copies or amplification to at least 12 copies per cell, averaged 17 per tumor. We have integrated these data with previous mutation analyses of the Reference Sequence genes in these same tumor types and have identified genes and cellular pathways affected by both copy number changes and point alterations. Pathways enriched for genetic alterations included those controlling cell adhesion, intracellular signaling, DNA topological change, and cell cycle control. These analyses provide an integrated view of copy number and sequencing alterations on a genome-wide scale and identify genes and pathways that could prove useful for cancer diagnosis and therapy.
amplification ͉ copy number changes ͉ Digital Karyotyping ͉ high-density SNP arrays ͉ homozygous deletion I t is well accepted that cancer is the result of the sequential mutations of oncogenes and tumor suppressor genes (1) . Historically, the discovery of these genes has been accomplished through analyses of individual candidate genes chosen on the basis of functional or biologic data. Recent advances in genomic technologies have permitted simultaneous evaluation of many genes, thereby offering more comprehensive and unbiased information (2, 3) . For example, the sequence of large families of genes, and even the human genes in the Reference Sequence (RefSeq) database, have been determined in subsets of human cancers (4, 5) . However, the alterations detected by sequencing represent only one category of genetic change that occurs in human cancer. Other alterations include gains (amplifications) and losses (deletions) of discrete chromosomal sequences that occur during tumor progression. Dramatic amplifications of oncogenes such as ERBB2 (6) or MYC (7) and deletions of tumor suppressor genes such as CDKN2A (8) , PTEN (9, 10) , and SMAD4 (11) have demonstrated the importance of these mechanisms of genetic alteration in particular tumor types. A comprehensive picture of genetic alterations in human cancer should therefore include sequence based alterations together with copy number gains and losses.
Evaluations of copy number changes in cancers using a variety of array types have been reported (12) . Several of the more recent studies used oligonucleotide arrays capable of distinguishing Ͼ100,000 genomic loci in colon, breast lung, pancreatic, skin cancers, and certain leukemias (13) (14) (15) (16) (17) (18) (19) (20) . However, identification of focal, high copy number amplifications, or homozygous deletions (HDs) have infrequently been reported, because many prior copy number analyses employing arrays have used genomic DNA purified from primary tumors. Primary tumors contain varying proportions of nonneoplastic cells thereby obscuring focal amplifications, defined by the increased copy number of a small region of the genome, from simple gains of whole chromosome arms. Furthermore, HDs can be difficult to discern in primary tumors because of confounding hybridization signals from nonneoplastic cells within the tumor (17) .
Many of the problems encountered with primary tumor samples can be overcome by use of early passage cancer cell lines or xenografts that are devoid of human nonneoplastic cells. Previous studies have shown that the process of generating such in vitro or in vivo cultures is not associated with the development of additional genetic alterations (21) . It is now widely recognized that HDs found in cell lines and xenografts represent true genetic alterations that are present in clonal fashion in primary tumors but are difficult to document in the latter as a result of the issues noted above (22, 23) .
In the current study, we examined xenografts or cell lines derived from breast and colorectal cancers to obtain high-resolution analyses of copy number and nucleotide alterations. Tumors were evaluated with arrays containing at least 317,000 SNP probes and selected samples were also evaluated with Digital Karyotyping (DK). This latter method provided a highly quantitative measure of gene copy number and was used to validate the sensitivity and specificity of the array data. The sequences of the 18, 191 genes from the RefSeq database determined for breast and colorectal cancers were integrated with these results, providing a genome-wide analysis of sequence and copy number alterations.
Results
Optimization of Copy Number Analysis with DK. DK was used as a standard to develop criteria for assessing amplifications and HDs with Illumina high-density SNP arrays [supporting information (SI) Fig. S1 and Table S1 ]. Analysis of DK libraries from 18 colorectal tumor samples identified a total of 21 amplification events, and four regions within the autosomal chromosomes where the tag density reached zero, representing HDs (Table S2) . As expected, we identified low-amplitude gains and losses of chromosome arms or other large genomic regions. We did not pursue these lowamplitude copy number changes as it is difficult to reliably identify candidate cancer genes from such large regions. To ensure that the copy number changes identified by DK were bona fide amplifications or HDs, we independently examined 12 alterations by quantitative PCR and confirmed the presence of the genomic alterations in every case examined.
We then directly compared DK data to those obtained through genomic hybridization of the same DNA samples to Illumina high-density oligonucleotide array (25, 26) . Using fluorescence intensity measurements, we developed an approach to detect HDs and amplifications resulting in Ն12 copies per nucleus (Ն6-fold amplification compared with the diploid genome) (see SI Methods).
Using this approach, all 14 amplification events and 3 HD events identified by DK in three representative tumor samples were detected by Illumina arrays (Table S1 and Fig. S2 ). In all cases, the genomic boundaries identified by both approaches were similar and within the resolution expected for both methods. No additional copy number changes of the sizes expected to be detected by DK were identified by the array approach in these samples. We did identify 25 additional small HDs (Ͻ250 kb in length) that would not have been possible to detect with DK given the number of tags analyzed (24) . To independently validate such smaller HDs, we used PCR and Sanger sequencing to examine genes located within small HDs and found that, in each case, multiple exons of each gene could not be amplified or sequenced. These results suggested that our approach for analysis of Illumina array data provided a sensitive and specific method for identification of amplifications and HDs, including relatively small alterations of either type.
Detection of Amplifications and HDs.
A total of 45 breast and 36 colorectal tumors were analyzed by Illumina arrays containing either Ϸ317,000 or Ϸ550,000 SNPs (Fig. S1 ). To determine the fraction of alterations that were likely to be somatic (i.e., tumorderived), we analyzed these regions in 23 matched normal samples. In the normal samples, no amplifications and only four distinct HDs were detected. We removed these alterations from further analysis, as well as those corresponding to known copy number variation in normal human cells (27, 28) . Finally, we removed any copy number changes where the boundaries were identical in two or more samples, because these were likely to represent germ-line variants. Based on this conservative strategy, we estimated that Ͼ95% of the 614 amplifications and 463 HDs (Table S3) represented true somatic alterations.
Breast cancers contributed to a majority of the alterations identified, comprising 68% and 80% of the total HDs and amplifications, respectively. Individual colorectal and breast tumors had on average 7 and 18 copy number alterations, respectively. Each colorectal cancer had an average of four HDs and three amplifications. Breast cancers had on average 7 HDs and 11 amplifications. Several of the tumor samples contained copy number alterations that were separated by short nonamplified or deleted sequences, presumably reflecting the complex structure of these alterations (29, 30) . The copy number alterations observed encompassed on average 1.7 and 2.4 Mb of colorectal and breast tumor haploid genomic sequence, respectively. The average numbers of proteincoding genes that were affected by amplification or HD were 24 and 9 per breast and colorectal cancer, respectively. Top seven candidate cancer genes for each tumor type are indicated. The combined group corresponds to genes that are altered in both tumor types, with at least one observed amplification. Minimal affected region is defined as the smallest overlapping interval affecting candidate cancer gene. Total number of amplifications indicates the number of focal amplifications or the number of focal and complex amplifications (in parentheses) in the indicated tumor type(s). Candidate cancer gene refers to either known cancer genes or the gene with the highest driver probability within the minimal affected region. Candidate genes were required to be entirely contained within the minimal affected region. The passenger probability provides a combined probability that the number of amplifications and point mutations observed were passengers alterations; these analyses used the intermediate passenger rate for point alterations (see SI Methods for additional information). All amplified genes and their passenger probabilities are indicated in Table S4 and the samples analyzed for such alterations are indicated in Table S6 .
Genes Altered in More than One Tumor. One of the main challenges in the analysis of somatic alterations in cancers involves the distinction between those changes that are selected for during tumorigenesis (driver alterations) from those that provide no selective advantage (passenger alterations). Even in regions that have multiple copy number alterations, this distinction can be particularly difficult because regions of amplification or HD can contain multiple genes, only a subset of which are presumably the underlying targets. We reasoned that the integration of copy number analyses with sequence data would help reveal driver genes that were more likely to contain genetic alterations. To accomplish this integration, we developed a statistical approach for determining whether the observed genetic alterations of any type in any gene were likely to reflect an underlying mutation frequency that was significantly higher than the passenger rate. To analyze the probability that a given gene would be involved in a copy number alteration, we made the conservative assumption that the frequency of all amplifications and HDs observed in each tumor type represented the passenger mutation frequency (i.e., we assumed that all copy number changes were passengers). The number of actual copy number alterations affecting each gene in all tumors was then compared with the simulated number of expected passenger alterations taking into account gene size, the distribution of SNP locations, and the frequency of passenger amplifications and HDs in breast and colorectal cancers.
We integrated these copy number analyses with the sequence data of the Sjöblom et al. and Wood et al. studies (5, 31) . In these studies, the protein coding sequences of 20,857 transcripts from the 18,191 genes in the RefSeq database were determined in breast and colorectal cancer samples, allowing detection of somatic sequence alterations. In the current study, the same 22 breast and colorectal tumor samples were analyzed in parallel by Illumina arrays, together with additional samples of each tumor type (Fig. S1 ). To integrate these different mutational data for each tumor type, we combined the probability that a gene was a driver gene based on the type and frequency of point mutations observed with the probability that the gene was a driver based on the number of observed amplifications and HDs (Fig. S1 ). Table 1 lists the loci that were amplified in at least one tumor and had the highest probability of containing driver genes as determined by the combined mutation analysis (a complete list of amplifications is provided in Table S3 and amplified genes in Table  S4 ). For genes to be considered potential targets of the amplification, the entire coding region of the gene was required to be contained within a focal amplicon. A few candidate genes in this list [e.g., CCNE1 (cyclin E) and ERBB2] were amplified in multiple tumors but were not found to be mutated by sequencing. The majority of candidate genes, however, harbored point mutations in some tumors and amplifications in others. The most striking aspect of this list of candidate genes is that only some of them had been implicated in cancer in the past: of the 19 genes indicated in Table  1 , only 8 had been implicated in tumorigenesis. The known cancer genes included MYC, ERBB2 (HER2/NEU), CCNE1, CCND1, EGFR, FGFR2, and IRS2, each of which had been shown to be amplified. In addition, MRE11, which was amplified in breast cancers, has been shown to be mutated in a subset of colorectal cancers and is thought to play an essential role in maintaining chromosomal stability (32) . Some genes were shown to be altered in both breast and colorectal cancers, with at least one of the tumors containing amplifications. Interestingly, among these genes, ERBB2 was found to be amplified in both breast and colorectal cancers, and FGFR2 was found to be mutated in breast cancers and amplified in colorectal cancers. Table 2 similarly lists the loci that were homozygously deleted in at least one tumor and had the highest probability of containing drivers as determined by the combined mutation analysis (a complete list of HDs is provided in Table S3 and homozygously deleted genes are listed in Table S5 ). For each of these genes, at least a Top seven candidate cancer genes for each tumor type are indicated. The combined group corresponds to genes that are altered in both tumor types, with at least one observed homozyous deletion. Minimal affected region is defined as the smallest overlapping interval affecting candidate cancer gene. Candidate cancer gene refers to either known cancer genes or the gene with the highest driver probability within the minimal affected region. Part of the coding sequence of the indicated candidate cancer gene was required to be contained within the minimal deleted region. The passenger probability provides a combined probability that the number of homozygous deletions and point mutations observed were passengers alterations; these analyses used the intermediate passenger rate for point alterations (see SI Methods for additional information). All amplified genes and their passenger probabilities are indicated in Table S4 and the samples analyzed for such alterations are indicated in Table S6 .
portion of the coding region was affected by the HD. A number of genes known to be inactivated in colorectal or breast tumorigenesis, such as CDKN2A, PTEN, and TP53 are found in this list. We also identified genes such as CHD5, MAP2K4, SMAD2, and SMAD3 that have been shown to be deleted in other tumor types but not in colorectal or breast cancers. Finally, we discovered a number of genes not known to be affected by HD in any tumor type. For example, HDs and point mutations were found in OMA1 and ZNF521 in colorectal cancers and in MANEA, PCDH8, SATL1, and ZNF674 in breast cancers. During the course of this study, we identified through independent experimentation that PCDH8 is mutated and homozygously deleted in breast cancer (33) .
Pathways Enriched for Copy Number and Point Alterations. We examined whether groups of genes belonging to certain cellular pathways were preferentially affected by genetic alterations. For this purpose, we developed a statistical approach that provided a probability that a pathway contained driver alterations, taking into account both the copy number changes and point mutations. Because the net effect of a pathway can be the same whether certain components are amplified or others deleted, all copy number alterations within a gene group were considered together. The analysis was performed by using well annotated GeneGo MetaCore databases (34) . For each gene group, we considered whether the component genes were more likely to be affected by point mutations, amplifications, or HDs, as compared with all genes analyzed using a modified version of gene set enrichment analysis (GSEA) (35) rather than the total number of mutations within individual groups. This approach limits the effects of single highly mutated Pathways correspond to GeneGO MetaCore pathway maps (MA), Gene Ontology groups (GO), or GeneGo groups (GG). The top 20 entries having at least two copy number alterations are indicated for each tumor type. Only pathways containing between 10 and 500 genes are included in this table. ЉAlterations in other tumor typeЉ corresponds to the number of copy number changes and point mutations observed in colorectal cancer when considering the pathways enriched for alterations in breast cancer and vice-versa for the pathways enriched for alterations in colorectal cancer. ЉQ valueЉ corresponds to the probability of obtaining the observed enrichment of alterations in each pathway through passenger alterations alone as described in SI Methods.
genes and requires the involvement of multiple genes to score a pathway as significantly affected.
These analyses identified gene groups that were enriched for genetic alterations in these tumor types (Table 3 ). In particular, the EGFR and ERBB gene pathways were enriched for alterations in both tumor types, involving various components of the PI3 kinase pathway (Fig. 1) . One-third of genes in these combined pathways were mutated by sequence alterations, amplifications, or HDs. Enrichment of alterations in other canonical gene groups including Notch and G 1 -S cell cycle transition pathways were also detected. The latter group included HDs of CDKN2A and CDKN2B genes and amplifications of cyclin D1, cyclin D3, and cyclin E3 genes in breast cancers. For all these gene groups, new genes were identified that had not been implicated by genetic alterations in these cellular processes. Finally, a variety of gene groups not known to be enriched for copy number changes in tumorigenesis were identified. These included genes implicated in cell-cell interaction and adhesion, including cadherins and metalloproteases. As an example, in colorectal cancers, a total of 33 cadherin and protocadherin genes were detected as being affected by copy number or sequence changes. In breast cancers, there was also enrichment in genes implicated in DNA topological control, including alterations in a number of topoisomerases (TOP1, TOP2A, TOP2B, and TOP3A) and helicases. Pathways showing significant enrichment for genetic alterations are listed in Table S7 .
Discussion
The integrated mutational analysis described herein provides a global picture of the genetic alterations of breast and colorectal cancers. The combination of sequencing and copy number analysis permits the identification of genes and pathways that may not be easily detected by either analysis alone.
The analysis of copy number changes can also provide general insights into the functional effects of point mutations. Singlenucleotide substitutions in genes that are observed to be deleted are more likely to be inactivating, whereas substitutions in genes that are amplified are more likely to be activating. This was confirmed by the observation of HDs and point mutations in TP53, SMAD2, SMAD3, and PTEN, all of which are thought to be tumor suppressors. If copy number changes faithfully reflect the overall effect of target genes, one would expect to infrequently see both amplifications and HDs of the same set of genes in human tumors. Accordingly, we observed an underrepresentation of genes that are homozygously deleted in one tumor and amplified in another [only 2 of the 1,148 altered genes identified were altered by both amplification and HD (P Ͻ 0.01, binomial test)].
These studies have several implications for future large-scale genomic analyses (36) . One is that the complexity of genetic alterations in human cancer increases when considering both point alterations and copy number changes. In addition to a median of 84 and 76 genes altered by point mutation, breast and colorectal cancers have a median of 24 and 9 genes altered by a major copy number change. These observations support a view of the breast and colorectal cancer genomic landscape where a few commonly affected ''gene mountains'' are scattered among a much larger number of ''gene hills'' that are infrequently altered by either point mutation or copy number changes. An example of a cancer genome landscape that incorporates copy number changes, illustrated in Fig. 2 , shows gene mountains and hills that result from the combined analysis.
Although cancer genome landscapes are complex, they may be better understood by placing all genetic alterations within defined cellular pathways. Our analyses identified several converging gene pathways, including the ERBB2, EGFR, and PI3K pathways, that were affected by copy number changes and point alterations in both breast and colorectal cancers. In addition, many pathways implicated in colorectal tumor progression (Notch, AKT, and MAPK) were enriched for alterations. Interestingly, many gene groups contained genes that were both amplified and others that were deleted, suggesting that different genes within the same group or pathway may be affected through alternate mechanisms. This is consistent with the observation that most signaling pathways contain both positive and negative regulators and alterations in any of these can lead to dysregulated signaling. Peaks indicate the 60 highest-ranking candidate cancer genes for each tumor type, with peak heights reflecting the passenger probability scores. The yellow peaks correspond to genes that are altered by copy number changes, whereas those altered only by point mutations are purple. The dots represent genes that were altered by copy number changes (red squares) or point mutations (white circles) in the B9C breast or Mx27 colorectal tumor samples. Altered genes participating in significant gene groups or pathways (Table S6 ) are indicated as black circles or squares.
The copy number and sequence alterations reported here should be placed in the context of other analyses to reveal the full compendium of molecular changes in a tumor cell. One limitation of our approach is that the copy number analyses we performed may have missed very small regions (Ͻ20 kb) that were amplified or deleted. Use of arrays with higher numbers of SNPs or larger DK libraries generated by using next-generation sequencing approaches will help improve the sensitivity of these analyses. Additionally, the incorporation of approaches that detect structural changes (e.g., translocations) and epigenetic alterations will likely prove to be useful. Finally, the statistical techniques we developed highlight the best candidates for future functional studies, but it remains possible that specific loci are more likely to be altered by copy number changes than others because they are located near fragile sites or other hotspots for recombination (37) . Therefore, these genetic analyses can only identify candidate genes that may play a role in cancer and do not definitively implicate any gene in the neoplastic process.
Several of the pathways identified affected a relatively high fraction of tumors and may be useful for cancer diagnosis or therapy. Alterations in signaling pathways of FGFR, EGFR, ERBB2, and PI3K were detected in nearly two-thirds of breast and colorectal tumors that were comprehensively examined in this study. These data suggest that the ERBB2 inhibitors may be useful not only in breast cancers but also in selected colorectal cancer patients in combination with existing therapeutic agents. Additionally, a significant fraction of the breast tumors analyzed had genetic alterations in genes regulating DNA topology. Although TOP2A is coamplified with ERBB2 and therefore does not represent the likely driver of this amplicon, alterations of TOP2A may still be of clinical utility. Because high doses of anthracyclines may improve clinical outcomes in breast cancer patients with TOP2A amplifications (38, 39) , our observations suggest that the additional alterations that we identified could be used to select patients that may respond to topoisomerasetargeted therapies. In a similar fashion, tumor cells deficient in certain cellular processes as a result of HDs could be targeted pharmacologically through synthetic lethality. In a general sense, our discovery that a typical colorectal or breast cancer has four to seven genes homozygously deleted suggests that further development of strategies targeting such HDs (40) could be widely applicable.
Materials and Methods
DNA samples from tumor-derived xenografts and cell lines were obtained and purified, and analyzed using DK and Illumina SNP arrays (24, 41) . Bioinformatic analyses were used to determine focal amplifications and HDs. Statistical methods were used to determine the likelihood that genetic alterations occurred at a frequency higher than the passenger rate and to identify gene groups enriched for copy number and sequence alterations. Detailed information for materials and methods is described in SI Methods. (1, 2) . All tumor samples analyzed for copy number analyses are listed in Table S7 . For the Illumina analyses, the colorectal cancer samples used were 10 cell lines and 26 xenografts, each developed from a liver metastasis of a different patient. The breast cancer samples used were 22 cell lines and 23 xenografts, each developed from a different patient. In addition, 11 colorectal cancer metastases [immunopurified using the BerEP4 antibody as described (3)], and seven cell lines were analyzed by Digital Karyotyping analyses. Available clinical information for samples that were analyzed by copy number and sequence analyses is available in table S2 of reference 2. All samples were obtained in accordance with the Health Insurance Portability and Accountability Act (HIPAA).
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Digital Karyotyping. Digital Karyotyping libraries were constructed as described (4, 5) . In brief, 17-bp tags of genomic DNA were generated using the NlaIII mapping and SacI fragmenting restriction enzymes. For each library, the experimental tags obtained were concatenated, cloned and sequenced. SAGE2002 software was used to extract the experimental tags from the sequencing data. The sequences of the experimental tags were compared to the predicted virtual tags extracted from the human genome reference sequence hg16 (NCBI Build 34, July 2003) and were visualized using the SageGenie DKView to identify potential alterations (http://cgap.nci.nih.gov/SAGE/DKViewHome). The coordinates of all identified alterations were translated to the human genome reference sequence hg17 (NCBI Build 35, May 2004) to allow comparison to Illumina data.
Homozygous deletions were identified using a sliding window size of 175 virtual tags (Ϸ700 kb in size). Windows with a tag density ratio (observed tags in window/expected tags in window) Ͻ0.01 were considered to represent putative homozygous deletions and were further examined. Regions of homozygous deletions were defined as containing no experimental tags and the boundaries were determined as the outermost virtual tags with no matching experimental tags.
Amplifications were identified using sliding windows of variable sizes, as the most accurate window size for detection and quantification of amplifications is the exact size of the altered region. Windows with tag density ratios Ն6 were considered to represent amplified regions. Boundaries of the amplified region were determined by the outermost tag contained in a window with a tag density ratio Ͼ3 or by the virtual tag position after which there is sharp decline in the observed experimental tags. The genotyping assay is a two step procedure that is based on hybridization to a 50 nucleotide oligo, followed by a two-color fluorescent single base extension. The image files of fluorescence intensities were processed using Illumina BeadStation software to provide intensity values for each SNP position. For each SNP, the normalized experimental intensity value (R) was compared to the intensity values for that SNP from a training set of normal samples and represented as a ratio (called the ''Log R Ratio'') of log 2 (R experimental /R training set ).
Bioinformatic Analysis of High-Density SNP Array Data. Digital Karyotyping was used to inform and optimize the criteria for detection of focal homozygous deletions and high-copy amplifications using the Illumina arrays. Three colorectal cancer samples (Co44, Co82, and Co84) were assessed by Digital Karyotyping tag libraries as well as the Illumina arrays (Table  S1 ). From these analyses criteria were developed to permit sensitive and specific detection of the Digital Karyotyping alterations using the Illumina platform as described below. These criteria were subsequently used to analyze an additional 46 breast and 33 colorectal cancers.
Detection of Homozygous Deletions. Homozygous deletions (HDs) were defined as two or more consecutive SNPs with a Log R Ratio value of ՅϪ2. The first and last SNPs of the identified HD region were considered to be the boundaries of the alteration for subsequent analyses. The deletion breakpoint would be expected to be located between the boundary deleted SNPs and adjacent non-deleted SNPs; use of the inner deleted SNP boundaries provides the most conservative approach as use of the outer boundaries may include non-deleted regions. To eliminate chip artifacts and potential copy number polymorphisms, we removed all HDs that were included in copy number polymorphism databases (6, 7) . As these analyses showed that copy number polymorphisms had conserved boundaries, we also removed all observed HDs with identical boundaries that occurred in multiple samples. Adjacent homozygous deletions separated by one or two SNPs were considered to be part of the same alteration. Adjacent HDs were evaluated separately for the purposes of determining affected genes, but were counted as single entries in Table 2 and Table S3 . To identify genes affected by HDs, we compared the location of coding exons in the RefSeq and CCDS databases with the genomic coordinates of the observed HDs. Any gene with a portion of its coding region contained within a homozygous deletion was considered to be affected by the deletion.
Detection of Amplifications. High copy amplifications (i.e., Ͼ12 chromosomal copies as determined by Digital Karyotyping) were defined as regions having at least one SNP with a LogR ratio Ն1.4, at least one in ten SNPs with a LogR ratio Ն1, and an average LogR ratio of the entire region of Ն0.9. The boundaries of amplified regions were delimited by the outermost SNPs with LogR ratios Ն1. Similar to analyses of homozygous deletions, we removed all amplifications that had identical boundaries in multiple samples.
Because focal amplifications are more likely to be useful in identifying specific target genes, a second set of criteria were used to remove large chromosomal regions or entire chromosomes that showed copy number gains. These large alterations, called ''complex amplifications,'' were thus distinguished from small focal alterations, called ''simple amplifications.'' Based on observations from Digital Karyotyping, several steps were used to identify and remove complex amplifications. First, amplifications Ͼ3Mb in size and groups of nearby amplifications (within 1 Mb) that were also Ͼ3Mb in size were considered complex. Amplifications or groups of amplifications that occurred at a frequency of Ն4 amplifications in a 10Mb region, or Ն5 amplifications per chromosome were deemed to be complex. The amplifications remaining after these filtering steps were considered to be simple amplifications and were further examined. The complex regions were not included in subsequent statistical analyses but those containing candidate cancer genes are indicated in Table 1 . To identify protein coding genes affected by amplifications, we compared the location of the start and stop positions of each gene within the RefSeq and CCDS databases with the genomic coordinates of the observed amplifications. As amplifications of a subgenic region (i.e., containing only a fraction of a gene) are less likely to have a functional consequence, we focused our analyses on genes whose entire coding regions were included in the observed amplifications.
A number of genes coamplified or codeleted with known oncogenes (CCND1, ERBB2, CCNE1, EGFR, MYC) or tumor suppressors (CDKN2A, PTEN, MAP2K4, TP53) were considered ''known passengers'' and eliminated from further statistical analysis. However, for completeness, these known passengers were listed along with their respective copy number alterations in Tables S3-S5 , but these alterations were not used to calculate the passenger probabilities listed in Tables S4 and S5 . Alterations of known passengers were also excluded from statistical analysis of pathways (Table S6 ).
Statistical Analysis of Deletions and Amplifications. For each of the genes involved in amplifications or deletions, we quantify the strength of the evidence that they may be drivers of carcinogenesis by reporting a driver probability, separately for amplifications and deletions. In each case, the passenger probability is an a posteriori probability that integrates information from the somatic mutation analysis of Wood et al. (2) with the data presented in this article. The passenger probabilities reported in Wood et al. (2) serve as a priori probabilities. These are available for three different scenarios of passenger mutation rates and results are presented separately for each. If a gene was not found to be mutated in Wood et al. (2) the prior passenger probability is set to the estimated proportion of passengers in the RefSeq set. Then, a likelihood ratio for ''driver'' versus ''passenger'' was evaluated using as evidence the number of samples in which a gene was found to be amplified (or deleted). Analysis is carried out separately by type of array, and then combined by multiplication of the relevant likelihood terms. The passenger term is the probability that the gene in question is amplified (deleted). For each sample, we begin by computing the probability that the observed amplifications (deletions) will include the gene in question by chance. Inclusion of all available SNPs is required for amplification, while any overlap of SNPs is sufficient for deletions. Specifically, if in a specific sample N SNPs are typed, and K amplifications are found, whose sizes, in terms of SNPs involved, are A 1 . A K , a gene with G SNPs will be included at random with probability
for amplifications and
We then compute the probability of the observed number of amplifications (deletions) assuming that the samples are independent but not identically distributed Bernoulli random variables, using the Thomas and Taub algorithm (8) , as implemented in R by M. Newton. Our approach to evaluating the passenger probabilities provides an upper bound, as it assumes that all of the deletions and amplifications observed only include passengers. The driver term of the likelihood ratio was approximated as for the passenger term, after multiplying the sample-specific passenger rates above by a gene-specific factor reflecting the increase (alternative hypothesis) of interest. This increase is estimated by the ratio between the empirical deletion rate of the gene and the expected deletion rate for that gene.
For each of the gene sets considered we quantify the strength of the evidence that they may include a higher-than-average proportion of driver genes. For each set, in a list of all of the RefSeq genes sorted by a score combining information on mutations, amplifications and deletions, we compared the ranking of the genes contained in the set with the ranking of those outside, using the rank-sum test, as implemented by the Limma package in Bioconductor (9) . Scores were obtained by adding three log likelihood ratios for mutations, amplifications and deletions. This combination approach makes an approximating assumption of independence of amplifications and deletions. In general, amplified genes cannot be deleted, so independence is technically violated. However, because of the relatively small number of dramatic amplification and deletions, this assumption is tenable for the purposes of gene set analysis. Inspection of the log likelihoods suggest that they are roughly linear in the number of events, supporting the validity of this approximation as a scoring system. The statistical significance of deviation from the null hypothesis of a random distribution was calculated using Limma and then corrected for multiplicity by the q-value method (10) as implemented in version 1.1 of the package ''q-value.'' Tag density ratio*
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